Skip to content

Effectiveness of Transvaginal Niche Resection Versus Expectant Management in Patients with Secondary Infertility and a Large Uterine Caesarean Scar Defect

Effectiveness of Transvaginal Niche Resection Versus Expectant Management in Patients with Secondary Infertility and a Large Uterine Caesarean Scar Defect (niche), a Randomised Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06599671
Acronym
TVARES
Enrollment
100
Registered
2024-09-19
Start date
2024-10-01
Completion date
2027-09-30
Last updated
2024-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caesarean Scar Defect

Keywords

caesarean scar defect

Brief summary

The goal of this clinical trial is to evaluate the efficacy and safety of transvaginal niche resection in improving pregnancy outcomes of a large uterine caesarean scar defect (niche) with secondary infertility. The main questions it aims to answer are: 1. Does transvaginal niche resection improve pregnancy outcomes of a large uterine caesarean scar defect (niche) with secondary infertility? 2. What medical problems do participants have when taking transvaginal niche resection? Researchers will compare transvaginal niche resection to expectant management (without any additional surgical intervention) to see if transvaginal niche resection works to improve pregnancy outcomes of a large uterine caesarean scar defect (niche) with secondary infertility. Participants will: 1. Undergo a procedure (transvaginal niche resection) within 2 week after randomization in the intervention group. Women were advised to use contraception in the first 6 months following niche resection to allow uterine healing prior to subsequent pregnancy. 2. Receive usual care at least 9 months which means no additional surgical intervention during this period in the control group. Patients are allowed to become pregnant and to receive fertility therapies if indicated. Any member of the control group who has not become pregnant after 9 months will be given the opportunity to undergo a transvaginal niche resection. 3. Receive a standardized magnetic resonance imaging (MRI) evaluation of the niches. Niches will be evaluated at baseline in all groups and at 3 months after surgery. 4. Be contacted by telephone at 6, 9 and 15 months to assess the primary and secondary outcomes.

Interventions

PROCEDURETransvaginal niche resection

In short: the bladder was carefully dissected away from the uterus towards the abdominal cavity to open the vesicovaginal space and reach the peritoneum. The fingers on the anterior wall isthmus could touch the obvious scar-like defect. The weak scar tissue then thoroughly was removed.

Sponsors

International Peace Maternity and Child Health Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
19 Years to 48 Years
Healthy volunteers
No

Inclusion criteria

1. It was diagnosed by MRI as a large niche (defined as niche with a depth of >50% of the myometrial thickness and a residual myometrial thickness (RMT) ≤3mm); 2. Infertility secondary to niche (the inability to conceive within 12 months of unprotected intercourse or repeated failed IVF); 3. Fertility requirements; 4. Signed informed consent.

Exclusion criteria

1. Age below 18 years or over 49 years; 2. Contraindications for intraspinal or general anaesthesia; 3. A (suspected) malignancy or combined benign lesions requiring hysterectomy; 4. Atypical endometrial cells or cervical dysplasia; 5. Uterine or cervical polyps; 6. Submucosal fibroids; 7. Hydrosalpinx.

Design outcomes

Primary

MeasureTime frameDescription
Live birth rateTotal follow-up will extend to 15 months after randomization.Live birth is defined as a live born neonate beyond 24 weeks of gestation.

Contacts

Primary ContactQunying Cai
invain05@163.com086 13621906294

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026